Rosen's Breast Pathology, 4e

411

Ductal Carcinoma In Situ

429. Haigh PI, Giuliano AE. The Coxet al. article reviewed. Oncology 1998;12:1293–1294. 430. Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment of breast cancer. Oncology 1998;12:1283–1292. 431. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011;223:307–317. 432. Han K, Nofech-Mozes S, Narod S, et al. Expression of HER2/neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) 2012;24:183–189. 433. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ ? Nature 2011;11:61–65. 434. Flanagan M, Love S, Hwang ES. Status of intraductal therapy for duc- tal carcinoma in situ . Curr Breast Cancer Rep 2010;2:75–82. 435. Bleicher RJ. Ductal carcinoma in situ . Surg Clin North Am 2013;93:393–410. 436. Berg CD. Resolving the ductal carcinoma in situ treatment conun- drum. J Natl Cancer Inst 2013;105:680–681. 437. Ballehaninna UK, Chamberlain RS. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilat- eral breast tumor recurrence nomogram predictability. J Clin Oncol 2011;29:e97–e98. 438. Bleyer A, Welch HG. Effect of three decades of screening mammogra- phy on breast-cancer incidence. N Engl J Med 2012;367:1998–2005. 439. Baur A, Bahrs SD, Speck S, et al. Breast MRI of pure ductal carcinoma in situ : sensitivity of diagnosis and influence of lesion characteristics. Eur J Radiol 2013;82:1731–1737.

421. Cheng L, Al-Kaisi NK, Gordon NH, et al. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease. J Natl Cancer Inst 1997;89:1356–1360. 422. Early Breast Cancer Trialists Collaborative Group. Effects of radiother- apy and of differences in the extent of surgery for early breast cancer on focal recurrence and on 15-year survival. Lancet 2005;366:2087–2106. 423. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a pre- dictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings fromNSABP protocol B-24. Breast Cancer Res Treat 2002;76:S36. 424. Liberman L, Van Zee KJ, Dershaw DD, et al. Mammographic fea- tures of local recurrence in women who have undergone breast- conserving therapy for ductal carcinoma in site. AJR Am J Roentgenol 1997;168:489–493. 425. Silverstein MJ, Gierson ED, Colburn WJ, et al. Can intraductal breast carcinoma be excised completely by local excision? Cancer 1994;73:2985–2989. 426. Goldstein NS, Kestin L, Vicini F. Pathologic features of initial bi- opsy specimens associated with residual intraductal carcinoma on reexcision in patients with ductal carcinoma in situ of the breast referred for breast-conserving therapy. Am J Surg Pathol 1999;23:1340–1348. 427. Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet? Cancer 1996;77:2189–2192. 428. Wood WC. Should axillary dissection be performed in patients with DCIS? Ann Surg Oncol 1995;2:193–194.